Inducing proliferation of human amniotic epithelial (HAE) cells for cell therapy.
Probably because amnion is derived from the fetus and is exposed to the maternal immune system, human amniotic epithelial (HAE) cells do not express the HLA-A, -B, -C, or -DR antigens on their surfaces, suggesting that HAE cells do not induce rejection (immune reaction) after allotransplantation. And the amnion, like the placenta, is useless to the mother and child after birth. Therefore, HAE cells or tissues were expected to be suitable for allotransplantation. Because HAE cells produce large amounts of enzymes, amnion transplantation has been carried out in order to correct inborn errors of metabolism by supplementing lysosomal enzyme deficiencies. However, several problems remain before amnion allotransplantation can be accepted as effective. The HAE cell population is limited, because the maximum number of HAE cells obtainable from one donor is about 2 x 10(8) cells, and HAE cells proliferate poorly in in vitro culture. In this study, we aimed at increasing the HAE cell population in vitro. First, we investigated the effect of several cytokines on HAE cell proliferation and found that hepatocyte growth factor (HGF), epidermal growth factor (EGF), and transforming growth factor-beta stimulated it, whereas IL-6 and LIF inhibited it. Second, we investigated the effects of amniotic fluid on HAE cell proliferation and observed that IL-6 in amniotic fluid inhibits it. Then, to inhibit the dying of cells, we attempted to inhibit apoptosis (one mode of cell death). Treatment with caspase III inhibitor increased the cell viability of HAE cells by 20%.
Terada
S
S
Department of Applied Chemistry & Biotechnology, Faculty of Engineering, Fukui University, Japan. terada@acbio.fukui-u.ac.jp
Matsuura
K
K
Enosawa
S
S
Miki
M
M
Hoshika
A
A
Suzuki
S
S
Sakuragawa
N
N
D000650:Amnion / Q000166:cytology*; D000653:Amniotic Fluid / Q000276:immunology; D017209:Apoptosis / Q000187:drug effects; D018929:Cell Culture Techniques / Q000379:methods; D002455:Cell Division; D017690:Cell Transplantation / Q000379:methods*; D002478:Cells, Cultured; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D016207:Cytokines / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000494:pharmacology; D004847:Epithelial Cells / Q000166:cytology* / Q000187:drug effects; D017228:Hepatocyte Growth Factor / Q000494:pharmacology; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology; D009842:Oligopeptides / Q000494:pharmacology
D015853:Cysteine Proteinase Inhibitors; D016207:Cytokines; D015850:Interleukin-6; D009842:Oligopeptides; C108637:aspartyl-glutamyl-valyl-aspartal; D004815:Epidermal Growth Factor; D017228:Hepatocyte Growth Factor